allyl-(3,4-dichloro-benzyl)-amine | 103038-64-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: allyl-(3,4-dichloro-benzyl)-amine
• 英文别名: Allyl-(3,4-dichlor-benzyl)-amin；N-[(3,4-dichlorophenyl)methyl]prop-2-en-1-amine
• CAS: 103038-64-8
• 化学式: C₁₀H₁₁Cl₂N
• mdl: MFCD07407750
• 分子量: 216.11
• InChiKey: PXNDPJQOMCOTNO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  光气 、 allyl-(3,4-dichloro-benzyl)-amine 生成 allyl(3,4-dichlorobenzyl)carbamic chloride
  参考文献：
  名称：

  FR2234293

  摘要：

  公开号：
• 作为产物：
  描述：

  3,4-二氯氯苄 、 丙烯胺 在 sodium hydroxide 作用下， 生成 allyl-(3,4-dichloro-benzyl)-amine 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Hypoglycemic Agents. II.^1—3 Arylbiguanides

  摘要：

  DOI：

  10.1021/ja01523a059

文献信息

• COMPOUND AND DRUG CONTAINING SAME
  申请人：Oita University Institute of Advanced Medicine, Inc.

  公开号：EP4104902A1

  公开（公告）日：2022-12-21

  The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.

  本公开提供一种化合物，可用于治疗和预防狂犬病。本公开提供一种由公式XXIF或公式XXIB表示的化合物：其中R1、R2A、R2B、R3和R4在规范中定义，溶剂或其药学上可接受的盐，使用这种化合物、溶剂或其药学上可接受的盐治疗或预防狂犬病和癌症，包括这种化合物、溶剂或其药学上可接受的盐的制药组合物，以及使用它们治疗或预防狂犬病和癌症的方法。
• COMPOUND FOR TREATMENT OF RABIES AND METHOD FOR TREATMENT OF RABIES
  申请人：Oita University Institute of Advanced Medicine, Inc.

  公开号：EP3838901A1

  公开（公告）日：2021-06-23

  The present disclosure provides a compound that is useful for the treatment and prevention of rabies. The present disclosure provides a compound represented by formula IF or formula IB: wherein R1, R2, R3, and R4 are defined in the specification, a solvate, or a pharmaceutically acceptable salt thereof, use of such compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prevention of rabies, a pharmaceutical composition comprising such compound, solvate, or pharmaceutically acceptable salt thereof, and a method for treating or preventing rabies using the same.

  本公开提供了一种可用于治疗和预防狂犬病的化合物。本公开提供了一种由式 IF 或式 IB 表示的化合物： 其中 R1、R2、R3 和 R4 在说明书中定义，其溶解物或其药学上可接受的盐，使用这种化合物、其溶解物或其药学上可接受的盐治疗或预防狂犬病，包含这种化合物、其溶解物或其药学上可接受的盐的药物组合物，以及使用这种化合物、其溶解物或其药学上可接受的盐治疗或预防狂犬病的方法。
• COMPOUNDS AND MEDICAMENTS USING SAME
  申请人：Oita University Institute of Advanced Medicine, Inc.

  公开号：US20210214356A1

  公开（公告）日：2021-07-15

  The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB: wherein R 1 , R 2A , R 2B , R 3 , and R 4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.
• 3,6-METHANO-1H-PYRROLO[3,2-b]PYRIDINE AND 3,6-METHANO-1H-PYRROLO[3,2-c]PYRIDINE COMPOUNDS AND MEDICAMENTS USING SAME
  申请人：Oita University Institute of Advanced Medicine, Inc.

  公开号：US20220194942A1

  公开（公告）日：2022-06-23

  The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIIF or formula XXIIB: wherein R 1 , R 2A , R 2B , R 3 , and R 4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.
• [EN] COMPOUND AND DRUG CONTAINING SAME<br/>[FR] COMPOSÉ ET MÉDICAMENT LE CONTENANT<br/>[JA] 化合物およびそれを利用した医薬
  申请人：OITA UNIV INSTITUTE OF ADVANCED MEDICINE INC

  公开号：WO2021161511A1

  公开（公告）日：2021-08-19

  本開示は狂犬病の治療および予防に有用な化合物を提供する。本開示は、式ＸＸＩＦまたは式ＸＸＩＢ：［式中、Ｒ１、Ｒ２Ａ、Ｒ２Ｂ、Ｒ３、およびＲ４は、明細書中に規定されるとおりである］により表される化合物、溶媒和物またはその薬学的に許容される塩、これらの化合物、溶媒和物またはその薬学的に許容される塩の狂犬病およびがんの治療または予防のための用途、これらの化合物、溶媒和物またはその薬学的に許容される塩を含む医薬組成物、およびそれを用いた狂犬病およびがんの治療および予防のための方法を提供する。